Sanofi to invest up to $8 billion with Regeneron on four next‑gen antibodies
Sanofi announced it will pay Regeneron $1 billion upfront and up to $7 billion in milestones to co‑develop four new antibody candidates that build on their Dupixent partnership. Regeneron will lead R&D while Sanofi will handle worldwide commercialization, and both will split development costs and future profits 50‑50. The agreement aims to replenish Sanofi’s pipeline before Dupixent’s patent expires.
Why it matters
The deal lifted Sanofi’s shares about 2% and Regeneron’s about 1% as investors view the funding as a hedge against Dupixent’s upcoming patent cliff. The partnership also secures non‑dilutive financing for Regeneron and gives Sanofi a pipeline of potential high‑revenue biologics.
Key facts
- 1Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestone payments. investing.com
- 2The four new antibody candidates target IL‑13, IL‑4xIL‑13 bispecific, IL‑4 and IL‑4Rα. finance.biggo.com
- 3Regeneron will lead research and development; Sanofi will lead global sales. investing.com
- 4Development and commercialization costs and any approved product profits will be split equally (50‑50). finance.biggo.com
- 5Dupixent sales rose 37.6% in Q2 to €5.154 billion. finance.biggo.com
- 6Sanofi’s shares rose about 2% and Regeneron’s about 1% on the announcement. investing.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.